FY2025 Earnings Estimate for ResMed Issued By Zacks Research

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research lifted their FY2025 EPS estimates for ResMed in a research note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $9.37 per share for the year, up from their previous estimate of $9.36. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.41 EPS, Q1 2026 earnings at $2.31 EPS, Q2 2026 earnings at $2.41 EPS, FY2026 earnings at $9.71 EPS and Q1 2027 earnings at $2.51 EPS.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

Several other equities research analysts have also recently commented on RMD. JPMorgan Chase & Co. boosted their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Friday, January 31st. KeyCorp boosted their price target on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Stifel Nicolaus dropped their price target on shares of ResMed from $250.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, March 5th. Finally, Citigroup upgraded ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $243.82.

ResMed Price Performance

Shares of NYSE RMD opened at $224.46 on Monday. ResMed has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The firm’s 50-day simple moving average is $236.09 and its 200 day simple moving average is $239.66. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The stock has a market cap of $32.97 billion, a P/E ratio of 26.50, a P/E/G ratio of 1.53 and a beta of 0.74.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed’s payout ratio is currently 25.03%.

Insider Transactions at ResMed

In other news, insider Kaushik Ghoshal sold 9,745 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,327,289.75. This trade represents a 50.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the sale, the director now directly owns 77,218 shares of the company’s stock, valued at $18,695,249.98. The trade was a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,940 shares of company stock valued at $9,164,385 in the last three months. Corporate insiders own 0.71% of the company’s stock.

Institutional Trading of ResMed

Several large investors have recently modified their holdings of RMD. Apollon Wealth Management LLC raised its holdings in ResMed by 15.1% in the 3rd quarter. Apollon Wealth Management LLC now owns 1,451 shares of the medical equipment provider’s stock worth $354,000 after acquiring an additional 190 shares during the period. GSA Capital Partners LLP bought a new position in shares of ResMed during the 3rd quarter worth about $410,000. Victory Capital Management Inc. increased its holdings in shares of ResMed by 11.4% during the 3rd quarter. Victory Capital Management Inc. now owns 116,710 shares of the medical equipment provider’s stock worth $28,491,000 after purchasing an additional 11,914 shares during the period. Huntington National Bank increased its holdings in shares of ResMed by 6.9% during the 3rd quarter. Huntington National Bank now owns 1,868 shares of the medical equipment provider’s stock worth $456,000 after purchasing an additional 120 shares during the period. Finally, Metis Global Partners LLC increased its holdings in shares of ResMed by 4.9% during the 3rd quarter. Metis Global Partners LLC now owns 6,790 shares of the medical equipment provider’s stock worth $1,658,000 after purchasing an additional 317 shares during the period. 54.98% of the stock is owned by institutional investors.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.